Collaboration and Partnership

Nerviano Medical Sciences S.r.l is focused on discovery and clinical development of small molecule NCEs for oncology. The company takes innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients.

Our current pipeline consists of NCEs, which all originate from our well validated oncology drug discovery platform, that span from early preclinical to clinical stage projects, and which are being developed both in house or with partners.
A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever evolving chemical collection with broad intellectual property coverage, know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib. Moreover, we are also developing a proprietary payload platform suitable for multiple partnering to generate novel Antibody-Drug Conjugates (ADC).

We collaborate worldwide with academia and clinical investigators as well as with industrial partners to advance our programs from early discovery to clinical development of new drugs.
We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising assets for clinical development.